ACP
RVMD icon

Acuta Capital Partners’s Revolution Medicines RVMD Stock Holding History

Acuta Capital Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,069
Closed -$2.54M – 27
2026
Q1 		$2.54M Buy
26,069
+17,658
+210% +$1.78M 1.79% 15
2025
Q4 		$670K Hold
8,411
– – 0.45% 26
2025
Q3 		$393K Sell
8,411
-47,282
-85% -$1.85M 0.41% 26
2025
Q2 		$2.05M Sell
55,693
-10,969
-16% -$421K 2.86% 13
2025
Q1 		$2.36M Sell
66,662
-45,038
-40% -$1.83M 2.73% 13
2024
Q4 		$4.89M Buy
111,700
+3,700
+3% +$187K 4.92% 8
2024
Q3 		$4.9M Sell
108,000
-25,000
-19% -$1.09M 3.97% 9
2024
Q2 		$5.16M Sell
133,000
-10,777
-7% -$403K 4.35% 9
2024
Q1 		$4.63M Sell
143,777
-16,223
-10% -$481K 3.01% 13
2023
Q4 		$4.59M Buy
+160,000
New +$3.84M 2.58% 17

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Acuta Capital Partners's RVMD Position: Q2 2026 in Review

Acuta Capital Partners sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 26,069 shares — an estimated $2.54M sold.

Acuta Capital Partners first reported a position in RVMD in Q4 2023 and held it in 10 quarters. The position peaked at $5.16M in Q2 2024. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Acuta Capital Partners reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Acuta Capital Partners sold 26,069 Revolution Medicines shares in Q2 2026, an estimated $2.54M.
  • Acuta Capital Partners first reported a position in Revolution Medicines in Q4 2023 and held it in 10 quarters.
  • Acuta Capital Partners's Revolution Medicines position peaked at $5.16M in Q2 2024.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.